Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
=== Possible Paleocene survivors === Non-avian dinosaur remains have occasionally been found above the K-Pg boundary. In 2000, Spencer Lucas and colleagues reported the discovery of a single hadrosaur right femur in the San Juan Basin of New Mexico, and described it as evidence of Paleocene dinosaurs. The rock unit in which the bone was discovered has been dated to the early Paleocene epoch, approximately 64.8 million years ago. If the bone was not re-deposited by weathering action, it would provide evidence that some dinosaur populations survived at least half a million years into the Cenozoic. Other evidence includes the presence of dinosaur remains in the Hell Creek Formation up to 1.3 m (4.3 ft) above the Cretaceous–Paleogene boundary, representing 40,000 years of elapsed time. This has been used to support the view that the K-Pg extinction was gradual. However, these supposed Paleocene dinosaurs are considered by many other researchers to be reworked, that is, washed out of their original locations and then reburied in younger sediments. The age estimates have also been considered unreliable.
During his tenure with the X-Men, Wolverine becomes a mentor for Kitty Pryde and later on Jubilee. Logan again encounters Jean, who has been resurrected and re-joins the X-Men, leading to resumption of Logan's rivalry with Cyclops. He is able to recall some of the trauma he received from the Weapon X program and tries to investigate his past, although his memories remain unreliable because of brainwashing and false memory implants. He meets Maverick, another former participant in the Weapon X project, and discovers that he had previously worked together with Sabretooth in Team X. During a conflict, the supervillain Magneto forcibly removes the adamantium from Wolverine's skeleton. This massive trauma causes his healing factor to burn out and leads to the discovery that his claws are actually bone. Wolverine leaves the X-Men for a time, embarking on a series of adventures during which his healing factor returns. After his return to the X-Men, Cable's son Genesis kidnaps Wolverine and attempts to re-bond adamantium to his skeleton. This is unsuccessful and causes Wolverine's mutation to accelerate out of control. He degenerates physically and mentally into a more primitive, bestial state. Elektra helps him to recover his humanity. Eventually, the villain Apocalypse captures Wolverine, brainwashes him into becoming the Horseman of Death, and successfully re-bonds adamantium to his skeleton. Wolverine overcomes Apocalypse's programming and returns to the X-Men.
=== Human Warnings === Difloxacin has been approved for animal use only. Keep out of reach of children. Avoid contact with eyes. In case of contact, immediately flush eyes with copious amounts of water for fifteen minutes. In case of dermal contact, wash skin with soap and water. Consult a physician if symptoms persists following exposure. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight.
=== Nutritional content === At birth, the composition of breast milk corresponds in quality to the specific needs of the infant. The pattern of intended nutrient content in breast milk is relatively consistent. Breastmilk is made from nutrients in the mother's bloodstream and bodily stores. It has an optimal balance of fat, sugar, water, and protein that is needed for a baby's age-appropriate growth and development. That being said, a variety of factors can influence the nutritional makeup of breastmilk, including gestational age, age of infant, maternal age, maternal smoking, and nutritional needs of the infant. The first type of milk produced is called colostrum. The volume of colostrum produced during each feeding is appropriate for the size of the newborn's stomach and is sufficient, calorically, for feeding a newborn during the first few days of life. Produced during pregnancy and the first days after childbirth, colostrum is rich in protein and Vitamins A, B12 and K, which support infants' growth, brain development, vision, immune systems, red blood cells, and clotting cascade. The breast milk also has long-chain polyunsaturated fatty acids which help with normal retinal and neural development. The caloric content of colostrum is about 54 Calories/100mL. The second type of milk is transitional milk, which is produced during the transition from colostrum to mature breast milk. As the breast milk matures over several weeks, the protein content decreases on average.
Sources: en.wikipedia.org
Leucine metabolism occurs in many tissues in the human body; however, most dietary leucine is metabolized within the liver, adipose tissue, and muscle tissue. Adipose and muscle tissue use leucine in the formation of sterols and other compounds. Combined leucine use in these two tissues is seven times greater than in the liver. In healthy individuals, approximately 60% of dietary L-leucine is metabolized after several hours, with roughly 5% (2–10% range) of dietary L-leucine being converted to β-hydroxy β-methylbutyric acid (HMB). Around 40% of dietary L-leucine is converted to acetyl-CoA, which is subsequently used in the synthesis of other compounds. The vast majority of L-leucine metabolism is initially catalyzed by the branched-chain amino acid aminotransferase enzyme, producing α-ketoisocaproate (α-KIC). α-KIC is mostly metabolized by the mitochondrial enzyme branched-chain α-ketoacid dehydrogenase, which converts it to isovaleryl-CoA. Isovaleryl-CoA is subsequently metabolized by isovaleryl-CoA dehydrogenase and converted to MC-CoA, which is used in the synthesis of acetyl-CoA and other compounds. During biotin deficiency, HMB can be synthesized from MC-CoA via enoyl-CoA hydratase and an unknown thioesterase enzyme, which convert MC-CoA into HMB-CoA and HMB-CoA into HMB respectively. A relatively small amount of α-KIC is metabolized in the liver by the cytosolic enzyme 4-hydroxyphenylpyruvate dioxygenase (KIC dioxygenase), which converts α-KIC to HMB.
Over 1,000 Kuwaiti civilians were killed by Iraqis. More than 600 Kuwaitis went missing during Iraq's occupation, and approximately 375 remains were found in mass graves in Iraq. The increased importance of air attacks from both coalition warplanes and cruise missiles led to controversy over the number of civilian deaths caused during Desert Storm's initial stages. Within Desert Storm's first 24 hours, more than 1,000 sorties were flown, many against targets in Baghdad. In one noted incident, two USAF stealth planes bombed a bunker in Amiriyah, killing 408 Iraqi civilians. Scenes of burned and mutilated bodies were subsequently broadcast, and controversy arose over the bunker's status, with some stating that it was a civilian shelter, while others contended that it was a center of Iraqi military operations, and that the civilians had been deliberately moved there to act as human shields. The Iraqi government claimed that 2,300 civilians died during the air campaign. A Project on Defense Alternatives study found that 3,664 Iraqi civilians were killed in the conflict. During the nationwide uprisings against the Ba'athist Iraqi government that directly followed the end of the Gulf War in March and April, an estimated 25,000 to 100,000 Iraqis were killed, overwhelmingly civilians. A Harvard University study released in June 1991 predicted that there would be tens of thousands of additional Iraqi civilian deaths by the end of 1991 due to the "public health catastrophe" caused by the destruction of the country's electrical generating capacity.
== The company == GenSpera president and CEO Craig Dionne, PhD, co-founded GenSpera in 2003. He was previously vice president of biological research at Cephalon Inc., where he was responsible for neurobiology and oncology drug discovery. GenSpera was financed by a series of private placements beginning in 2007 and became publicly traded in late 2009.
The Greater Manchester Integrated Transport Authority (GMITA) was a local government institution responsible for the strategic direction of passenger transport in Greater Manchester. It existed from 1969 to 1974 as the SELNEC Passenger Transport Authority and was then replaced by Greater Manchester County Council. It was created again in 1986 as the Greater Manchester Passenger Transport Authority. It was renamed in 2008 as the Greater Manchester Integrated Transport Authority. Policy of the authority was delivered by the Greater Manchester Passenger Transport Executive. It was replaced by the Greater Manchester Combined Authority in 2011.
Adrenomedullin (AM) exerts its actions through combinations of the calcitonin receptor-like receptor (CALCRL) or CLR; and either (Receptor activity-modifying protein) 2 (RAMP2) or RAMP3, (known as AM1 and AM2 receptors, respectively). Both transduce the hormone binding to intracellular signaling via second messenger cascades. The AM2 receptor has a low affinity for CGRP, but this is of no physiological relevance. Unlike the classical one ligand-one receptor notion of receptor signalling, the interaction of both CALCRL and RAMP at the membrane is required for AM to mediate its action: neither can bind the hormone (and therefore transduce a signal) alone. Stimulation by AM of its receptor increases production of both cyclic AMP (cAMP) and nitric oxide. Before the discovery of the RAMPs and the identification of heteromeric receptors for the calcitonin family of peptides, a single G Protein coupled Adrenomedullin receptor was identified, but more recent reports have cast doubts as to its importance in the major effects of adrenomedullin. In more recent research, the roles of the AM1 and AM2 receptors have been clarified through studies in genetically manipulated mice. The adrenomedullin knockout is an embryonic lethal phenotype that dies mid-gestation from a condition known as hydrops fetalis. The CALCRL or CLR KO mouse recapitulates the same phenotype, as it lacks both the AM1 and AM2 receptors (incidentally confirming the lack of physiological significance for the earlier single protein AM receptor discovered by Kapas).
Sources: en.wikipedia.org
A GnRH modulator, or GnRH receptor modulator, also known as an LHRH modulator or LHRH receptor modulator, is a type of medication which modulates the GnRH receptor, the biological target of the hypothalamic hormone gonadotropin-releasing hormone (GnRH; also known as luteinizing-releasing hormone, or LHRH). They include GnRH agonists and GnRH antagonists. These medications may be GnRH analogues like leuprorelin and cetrorelix – peptides that are structurally related to GnRH – or small-molecules like elagolix and relugolix, which are structurally distinct from and unrelated to GnRH analogues. GnRH modulators affect the secretion of the gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn affects the gonads, influencing their function and hence fertility as well as the production of sex steroids, including that of estradiol and progesterone in women and of testosterone in men. As such, GnRH modulators can also be described as progonadotropic or antigonadotropic, depending on whether they act to increase or decrease gonadotropins. Shortly after the discovery of GnRH by Nobel laureates Guillemin and Schally, researchers tried to modify the GnRH decapeptide with the intent to create analogues that could activate or block the receptor. Subsequent to the development and introduction of GnRH analogues, non-peptide or small-molecule GnRH modulators were developed and introduced. All GnRH modulators are contraindicated in pregnancy (pregnancy category X).
=== Order of events === For birth of a de novo protein-coding gene to occur, a non-genic sequence must both be transcribed and acquire an ORF before becoming translated. These events could occur in either order, and there is evidence supporting both an "ORF first" and a "transcription first" model. An analysis of de novo genes that are segregating in D. melanogaster found that sequences that are transcribed had similar coding potential to the orthologous sequences from lines lacking evidence of transcription. This finding supports the notion that many ORFs can exist prior to being transcribed. The antifreeze glycoprotein gene AFGP, which emerged de novo in Arctic codfishes, provides a more definitive example in which the de novo emergence of the ORF was shown to precede the promoter region. Furthermore, putatively non-genic ORFs long enough to encode functional peptides are numerous in eukaryotic genomes, and expected to occur at high frequency by chance. Through tracing the evolution history of ORF sequences and transcription activation of human de novo genes, a study showed that some ORFs were ready to confer biological significance upon their birth. At the same time, transcription of eukaryotic genomes is far more extensive than previously thought, and there are documented examples of genomic regions that were transcribed prior to the appearance of an ORF that became a de novo gene.
== Marketing == A 2024 editorial described a direct-to-consumer marketing email from a company in Arizona advertising a "3 for 1" sale on Exosomes or Whartons Jelly. The email stated that the products are "manufactured in an FDA-registered, cGMP compliant, ISO certified lab", but did not mention that such birth products can be used only in a registered clinical trial, according to a directive from the United States Food and Drug Administration on May 31, 2021.
=== Prostate cancer === Sarcosine has been debated as a biomarker for prostate cancer cells. Other research has suggested that sarcosine plays an active role in the progression of prostate cancer, as addition of sarcosine to prostate epithelial cells caused the emergence of a new invasive phenotype.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.